Pharma

1,300 eligible for Sanofi's 'voluntary departures'

About 1,300 Sanofi-Aventis employees will be eligible for the "voluntary departures" that are part of the company restructuring announced yesterday. Report

GSK cancer unit, in 'building mode,' gets picky with M&A

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

by Carly Helfand Jan 17, 2020 12:40pm

Pharma

Novo's Ozempic scores major win with heart-helping FDA approval

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

by Kyle Blankenship Jan 17, 2020 9:21am

Pharma

Bayer's 'tumor-agnostic' Vitrakvi rejected in England, Germany

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

by Eric Sagonowsky Jan 17, 2020 10:41am

Pharma

1,300 eligible for Sanofi's 'voluntary departures'

Suggested Articles

GSK cancer unit, in 'building mode,' gets picky with M&A

Novo's Ozempic scores major win with heart-helping FDA approval

Bayer's 'tumor-agnostic' Vitrakvi rejected in England, Germany